Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
- Teva generic entry potentially set for 2 September 2032
- Settlement resolves Mayne Pharma’s final IMVEXXY Paragraph IV dispute
- No financial payment or upfront consideration between the parties
- IMVEXXY net sales rose 8% to US$29.3 million
- IMVEXXY patent portfolio includes a patent expiring in February 2034
Teva dispute sets 2032 generic entry date
Mayne Pharma Group Limited (ASX:MYX) has cleared the last outstanding US patent dispute over its menopause product IMVEXXY, agreeing with Teva Pharmaceuticals USA on a potential generic market entry date of 2 September 2032. The settlement remains subject to court approval and allows earlier entry in certain circumstances that the announcement does not specify.
The agreement resolves litigation that began in April 2020 over IMVEXXY’s FDA Orange Book-listed patents. It includes no financial payment or upfront monetary consideration between the parties. Together with the Sun Pharma settlement for IMVEXXY, announced on 30 September, the Teva deal leaves Mayne with no ongoing Paragraph IV litigation relating to the product.
IMVEXXY remains a growing commercial asset
IMVEXXY is a locally administered estradiol vaginal insert used to treat moderate to severe dyspareunia associated with menopause. In the 12 months to 30 June 2026, total prescriptions increased 6% from the prior corresponding period, while net sales rose 8% to US$29.3 million.
Mayne said the settlements provide greater clarity on the generic entry landscape and remove the cost and uncertainty of continuing litigation. The company also said it will continue investing in access, adherence and prescriber engagement across its Women’s Health portfolio.
Patent protection extends beyond the agreed entry date
Mayne said its last-expiring IMVEXXY patent runs until February 2034, although the agreed Teva entry date falls earlier and remains conditional on court approval. That distinction matters: the settlement establishes a pathway for potential commercial entry, but it does not mean Teva will necessarily enter on that date or that all patent protection ends then.
The next concrete markers are approval of the settlement and disclosure of any circumstances that could permit earlier entry. For Mayne, the legal uncertainty has narrowed, but the longer-term commercial question is how IMVEXXY sales develop before generic competition can begin.
Bottom Line?
The litigation overhang has largely lifted, but IMVEXXY’s value now depends on sales momentum, court approval and the conditions around any earlier generic entry.
Questions in the middle?
- Will the court approve the Teva settlement without changes to the proposed entry framework?
- What circumstances could allow Teva to enter before 2 September 2032?
- Can IMVEXXY maintain prescription and sales growth while Mayne prepares for eventual generic competition?